|Bid||39.25 x 0|
|Ask||39.28 x 0|
|Day's Range||38.61 - 39.58|
|52 Week Range||27.70 - 39.58|
|Beta (3Y Monthly)||0.17|
|PE Ratio (TTM)||25.86|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||0.94 (2.44%)|
|1y Target Est||36.31|
Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed. Worldwide sales of Signifor® in 2018 were $ 72 million.
Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, today reported that its strategy aimed at establishing a direct presence in the key markets across all continents has been successfully executed. Local Recordati Rare Diseases companies are now active in North America, Latin America, Europe, MENA (Middle East and North Africa) and Asia Pacific.
Q1 2019 Recordati Industria Chimica e Farmaceutica SpA Earnings & 2019-2021 Business Plan Call
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED. Consolidated revenues € 383.0 million, +4.5%.EBITDA (1) € 143.9 million,.
Recordati’s first quarter 2019 results and the Group’s development strategy and objectives for the period 2019-2021 will be presented at this meeting. Recordati is a partner of choice for new product licenses for its territories.
RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017). Shareholders approve the 2018 results: consolidated revenues € 1,352.2 million.
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4.
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%. Consolidated.
Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan. The agreement includes a right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion. Upon signing of the agreement an upfront payment of $ 25 million is due to Aegerion, in addition to a near term milestone of $ 5 million.
Italian drugmaker Zambon is looking to China and the U.S. to grow its respiratory and nervous system portfolio and could spend more than 100 million euros ($114 million) on the right acquisition, its chief executive said. The family-owned pharma group, famous for its mucolytic agent Fluimucil, used to treat respiratory problems, has cash enough to fund expansion plans but could contemplate a stock market listing if a big opportunity arose. "It's not on the table at the moment, but we could consider it if a large-scale project comes along," Roberto Tascione told Reuters in an interview.
Recordati announces the signing of an agreement for the acquisition of 100% of the share capital of Tonipharm S.A.S., a French company based in Boulogne-Billancourt near Paris, active mainly in the self-medication market with over-the-counter (OTC) products. Tonipharm was established in 1991 and promotes a wide portfolio of self-medication products together with some prescription drugs. The company’s sales are generated mainly by the line of products sold under the umbrella brand Ginkor, OTC treatments based on ginko biloba which are very well known on the French market.
Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a Recordati group company dedicated to providing treatment for patients with unmet medical needs suffering from rare diseases, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, granting Orphan Europe exclusive rights to Ledaga® worldwide, excluding the United States, China, Hong Kong and Israel. The product has been granted Orphan Drug Designation in Europe and is approved by the European Commission subject to post approval commitments.
Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding returns in the long run. Historically, Recordati Industria Chimica e Farmaceutica Read More...
Attention dividend hunters! Recordati Industria Chimica e Farmaceutica SpA (BIT:REC) will be distributing its dividend of €0.45 per share on the 21 November 2018, and will start trading ex-dividend in Read More...
Milan, 5 November 2018 –Recordati today announced that the European Commission (EC) has granted Orphan Drug Designation to Orphan Europe’s (a Recordati group company) investigational product REC 0545 for the treatment of maple syrup urine disease (MSUD). This is the first time that an Orphan Drug Designation has been granted in this indication.
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Family-owned Italian biopharmaceutical group Dompe Farmaceutici is considering a listing of its shares as it looks to focus more on its biotech business and treating specific diseases. "In 3-4 years we could consider a flotation perhaps in the U.S.," Chief Executive Sergio Dompe said. Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger - or buying a listed business - in the United States, one of the company's key markets.
The big shareholder groups in Recordati Industria Chimica e Farmaceutica SpA (BIT:REC) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
I am going to run you through how I calculated the intrinsic value of Recordati Industria Chimica e Farmaceutica SpA (BIT:REC) by taking the foreast future cash flows of theRead More...